SGLT2 Inhibitors: Emerging Roles In The Protection Against Cardiovascular And Kidney Disease Among D

Since type 2 diabetes mellitus (T2DM) represents a prevalent disease with the severe clinical implications, researchers herein analyzed the recent revelations on sodium-glucose co-transporter type 2 (SGLT2) inhibitors which have demonstrated to have beneficial cardiovascular as well as kidney-related impacts. In recent placebo-controlled clinical trials, SGLT2 inhibitors displayed the ability to reduce cardiovascular death, progression of kidney disease, and all-cause death in diabetic and non-diabetic patients. These medications are shown to have immense utility in the treatment of patients with T2DM. Findings showed these agents brought about decrease in the progression to advanced forms of kidney disease as well as its associated complications. As SGLT2 inhibitors provide protection against cardiovascular/renal death as well as improve all-cause mortality, these medications are recommended to be front and center in the treatment of patients with diabetic kidney disease with and without chronic kidney disease.

​

Source